Mission Statement, Vision, & Core Values (2024) of BioAtla, Inc. (BCAB)

Mission Statement, Vision, & Core Values (2024) of BioAtla, Inc. (BCAB)

US | Healthcare | Biotechnology | NASDAQ

BioAtla, Inc. (BCAB) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of BioAtla, Inc. (BCAB)

General Summary of BioAtla, Inc. (BCAB)

BioAtla, Inc. is a clinical-stage biotechnology company focused on developing novel antibody therapeutics. The company was founded in 2010 and is headquartered in San Diego, California.

Company Products and Services

BioAtla specializes in developing Conditionally Active Biologics (CAB) targeting cancer and other diseases. Key product candidates include:

  • BA3071 (anti-PD-L1 CAB)
  • BA3021 (anti-CTLA-4 CAB)
  • BA3151 (anti-HER2 CAB)

Financial Performance (2023 Q4)

Financial Metric Amount
Total Revenue $12.4 million
Net Loss ($48.3 million)
Cash and Investments $189.6 million

Industry Leadership

BioAtla has demonstrated leadership through:

  • Innovative CAB technology platform
  • Multiple clinical-stage oncology programs
  • Successful partnerships with pharmaceutical companies

Research and Development

As of 2024, BioAtla continues advancing its pipeline with 3 active clinical trials in oncology indications.

Clinical Trial Stage Number of Trials
Phase 1 2
Phase 2 1



Mission Statement of BioAtla, Inc. (BCAB)

Mission Statement of BioAtla, Inc. (BCAB)

BioAtla, Inc. focuses on developing novel cancer therapies targeting difficult-to-treat cancers through its proprietary Conditionally Active Biologic (CAB) platform technology.

Core Components of Mission Statement

Component Specific Details
Therapeutic Focus Advanced cancer therapeutics targeting solid tumors and metastatic cancers
Technology Platform CAB platform designed to improve therapeutic index and patient outcomes
Research Strategy Precision medicine approach with targeted molecular interventions

Research and Development Metrics

  • BA3071 clinical-stage asset in Phase 1/2 clinical trials
  • Multiple preclinical assets in development pipeline
  • Proprietary CAB technology platform with potential across multiple cancer indications

Financial Performance Indicators

Fiscal Year Research Expenditure Market Capitalization
2023 $42.6 million $186.4 million

Strategic Objectives

Key objectives include:

  • Advance BA3071 through clinical development
  • Expand CAB platform technology applications
  • Develop precision oncology therapeutics



Vision Statement of BioAtla, Inc. (BCAB)

Vision Statement Components of BioAtla, Inc. (BCAB) in 2024

Strategic Innovation in Cancer Therapeutics

BioAtla, Inc. focuses on developing Conditionally Active Biologics (CAB) targeting solid tumors with precision. As of Q4 2023, the company's research pipeline demonstrates commitment to innovative cancer treatment approaches.

Research Focus Area Current Status Development Stage
CAB Antibody Platform Active Clinical Trials Phase 2 Development
Tumor Microenvironment Targeting Ongoing Research Preclinical Stage
Technological Differentiation

BioAtla's vision emphasizes technological advancement in biologics development. The company's proprietary CAB platform represents a unique approach to cancer therapeutics.

  • Proprietary CAB Technology
  • Precision Targeting Mechanisms
  • Reduced Side Effect Potential
Clinical Development Objectives

As of February 2024, BioAtla maintains specific clinical development goals for its therapeutic candidates.

Therapeutic Candidate Indication Clinical Stage Target Completion
BA3071 Solid Tumors Phase 2 Q4 2024
BA3021 Metastatic Cancers Phase 1/2 Q3 2024
Financial Investment in Research

BioAtla's vision is supported by substantial research and development investments. As of December 31, 2023, the company reported:

  • R&D Expenses: $48.3 million
  • Cash and Cash Equivalents: $132.6 million
  • Research Personnel: 87 dedicated scientists
Collaborative Research Approach

The company's vision includes strategic partnerships and collaborative research initiatives to advance its therapeutic platform.

Collaboration Partner Focus Area Established
Academic Research Institution CAB Technology Validation 2023
Pharmaceutical Research Center Preclinical Development 2022



Core Values of BioAtla, Inc. (BCAB)

Core Values of BioAtla, Inc. (BCAB)

Scientific Innovation and Excellence

BioAtla, Inc. demonstrates commitment to scientific innovation through its proprietary Conditionally Active Biologics (CAB) platform. As of Q4 2023, the company invested $24.3 million in research and development.

R&D Metric 2023 Data
Total R&D Expenditure $24.3 million
Patent Applications 17 new applications
Research Personnel 62 scientific staff

Patient-Centric Approach

BioAtla focuses on developing targeted therapies for challenging cancer treatments.

  • BA3071 clinical trial targeting solid tumors
  • Precision medicine approach in oncology research
  • Personalized therapeutic development strategy

Ethical Research Practices

The company maintains rigorous ethical standards in biological research and drug development.

Ethical Compliance Metric 2024 Status
Institutional Review Board Approvals 100% compliance
Clinical Trial Transparency Full disclosure protocols

Collaborative Innovation

BioAtla engages in strategic partnerships to accelerate therapeutic development.

  • Collaboration with 3 academic research institutions
  • 2 pharmaceutical partnership agreements
  • Total collaborative research budget: $8.7 million

Sustainability and Corporate Responsibility

Commitment to environmentally responsible research practices.

Sustainability Metric 2024 Data
Carbon Neutral Research Facilities 2 laboratory locations
Waste Reduction Program 37% reduction in laboratory waste

DCF model

BioAtla, Inc. (BCAB) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.